There has been growing momentum among policymakers to address rising prescription drug prices. One solution is leveraging market forces to bring down costs by increasing competition through generics and biosimilars. During this webinar, panelists will evaluate how increasing the number of generics and biosimilars on the market may affect the drug prices. Specifically, panelists will discuss the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.
Mary Ella Payne, MSPH, RN, Acting President and Chief Executive Officer, Alliance for Health Policy
- Amy Gutierrez, PharmD, Vice President and Chief Pharmacy Officer, Kaiser Permanente National Pharmacy Programs
- Dora Hughes, MD, Senior Policy Advisor, Sidley Austin LLP
*Please note that the panel may change due to the addition of speakers*
The Alliance for Health Policy gratefully acknowledges the support of the National Institute for Health Care Management (NIHCM) for this event.